Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | US

Overview

Corporate Details

ISIN(s):: US0197701065
LEI:
Country:: United States of America
Address:: 210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://allogene.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NOVAVAX INC Develops and commercializes nanoparticle vaccines for serious infectious diseases.	United States of America	NVAX
NovMetaPharma Co., Ltd. Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.	South Korea	229500
Novo Nordisk Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.	Denmark	NOVO
NRX Pharmaceuticals, Inc. Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.	United States of America	NRXP
NuCana plc Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.	United States of America	NCNA
NUFORMIX PLC Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.	United Kingdom	NFX
Nurix Therapeutics, Inc. Developing protein degradation medicines to treat cancer and autoimmune diseases.	United States of America	NRIX
NUTEX Investments Plc Develops & distributes health, cosmetic & pharma products from natural ingredients globally.	Hungary	NUTEX
NutriBand Inc. Develops abuse-deterrent transdermal patches to make potent drug delivery safer.	United States of America	NTRB
Nuvalent, Inc. Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.	United States of America	NUVL